MedTrace Logo

Assessing Bioavailability of CoQ10 Supplementation in Burn Patients

NCT02251626 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-09-15

No results posted yet for this study

Summary

To test the hypotheses that plasma and intracellular coenzyme Q10 levels will decline after burn injury and that ubiquinol supplementation will increase plasma and intracellular coenzyme Q10 levels in burn patients.

To test the hypothesis that ubiquinol supplementation ameliorates mitochondrial dysfunction/disintegrity and metabolic derangements, and decreases circulating alarmins (a.k.a. endogenous DAMPs) in burn patients as compared with placebo.

Conditions

  • Burn Injury

Interventions

DIETARY_SUPPLEMENT

coenzyme Q10

It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.

DIETARY_SUPPLEMENT

Placebo

It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.

Sponsors & Collaborators

  • Kaneka Medical America LLC

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Masao Kaneki, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-04-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02251626 on ClinicalTrials.gov